엘앤씨바이오 (290650.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	116.3B	85.5B	72.1B	68.9B	52.6B
Cost of Revenue	49.7B	44.2B	36.4B	32.1B	25.6B
Gross Profit	66.6B	41.3B	35.7B	33.9B	27.0B
Operating Expenses
R&D Expense	3.0B	4.1B	4.9B	3.2B	2.2B
SG&A Expense	33.2B	22.9B	18.2B	20.5B	13.9B
General & Admin Expense	16.4B	4.2B	2.1B	2.9B	1.9B
Selling & Marketing Expense	16.7B	18.7B	16.1B	11.1B	7.5B
Other Expenses	10.9B	10.9B	10.1B	2.1B	1.4B
Total Operating Expenses	47.1B	37.9B	33.2B	25.7B	17.5B
Cost and Expenses	96.9B	82.0B	69.6B	61.1B	43.1B
Operating Income (EBIT)	19.4B	3.4B	2.5B	7.0B	9.5B
Non-Operating
Interest Income	(3.7B)	1.3B	1.6B	1.5B	562.5M
Interest Expense	(10.0B)	5.9B	3.2B	6.2B	3.1B
Net Interest Income	6.3B	(4.6B)	(1.7B)	(4.6B)	(2.5B)
Other Non-Op Income/Expense	(168.9B)	(163.5B)	135.3B	55.2B	(4.9B)
Non-Operating Income (excl Interest)	158.6B	—	(138.5B)	(2.1B)	1.0B
EBT (Pre-Tax Income)	(149.5B)	(160.0B)	137.8B	62.9B	4.6B
Income Tax Expense	(228.3M)	(21.7B)	(5.4B)	14.4B	(1.1B)
Bottom Line
Net Income	(149.5B)	(138.2B)	141.1B	48.4B	4.5B
Earnings from Cont. Ops	(149.3B)	(138.4B)	143.2B	48.9B	5.7B
Earnings from Discont. Ops	528.8M	321.5M	(2.3B)	(328.0M)	—
Bottom Line Net Income	(149.4B)	(138.2B)	141.1B	48.4B	4.5B
Per Share
Basic EPS	(₩3,085)	(₩2,906)	₩3,110	₩1,066	₩100
Diluted EPS	(₩3,085)	(₩2,906)	₩2,864	₩1,053	₩100
Revenue Per Share	₩2,156	₩1,736	₩1,589	₩1,493	₩1,159
Shares
Basic Shares Outstanding	53.9M	49.2M	45.4M	46.1M	45.4M
Diluted Shares Outstanding	53.9M	49.2M	50.4M	49.4M	45.4M
Profitability Metrics
EBITDA	17.2B	11.6B	147.8B	14.8B	13.0B
D&A	9.0B	8.1B	6.8B	5.7B	4.5B
EBIT	8.2B	3.4B	141.0B	9.1B	8.4B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026